(Q35181801)

7 August 2017

1 reference

title

The glucagon-like peptides: a double-edged therapeutic sword? (English)

1 reference

7 August 2017

TracyAnn Perry

1

1 reference

7 August 2017

Nigel H Greig

series ordinal

2

1 reference

7 August 2017

publication date

1 July 2003

1 reference

Trends in Pharmacological Sciences

7 August 2017

published in

1 reference

7 August 2017

volume

24

1 reference

7 August 2017

issue

7

1 reference

7 August 2017

page(s)

377-383

1 reference

Interactions between insulin resistance and insulin secretion in the development of glucose intolerance

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

GIP or not GIP? That is the question

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Ileal release of glucagon-like peptide-1 (GLP-1)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

A role for glucagon-like peptide-1 in the central regulation of feeding

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Structural characterization by affinity cross-linking of glucagon-like peptide-1(7-36)amide receptor in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

The role of the gut in regulating food intake in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Neurotrophin-4/5 protects hippocampal and cortical neurons against energy deprivation- and excitatory amino acid-induced injury

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Pharmacological agents that directly modulate insulin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Expression of cAMP-regulated guanine nucleotide exchange factors in pancreatic beta-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

A family of cAMP-binding proteins that directly activate Rap1

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Is CREB a key to neuronal survival?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Neuroprotective and neurorestorative signal transduction mechanisms in brain aging: modification by genes, diet and behavior.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2803%2900160-3

7 January 2021

10.1016/S0165-6147(03)00160-3

Identifiers

DOI

1 reference

7 August 2017

1 reference